Vertex Pharmaceuticals (VRTX) Common Equity (2009 - 2026)

Vertex Pharmaceuticals' Common Equity history runs 18 years deep, the most recent figure standing at $19.4 billion for Q1 2026.

• In Q1 2026, Common Equity rose 17.37% year-over-year to $19.4 billion; the TTM figure through Mar 2026 stood at $19.4 billion (up 17.37% YoY), while the FY2025 annual figure was $18.7 billion, up 13.75% from the prior year.
• Common Equity was $19.4 billion for Q1 2026 at Vertex Pharmaceuticals, up from $18.7 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $19.4 billion in Q1 2026 to a low of $10.9 billion in Q1 2022.
• Historically, Common Equity has averaged $15.8 billion across 5 years, with a median of $16.4 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Common Equity jumped 37.75% in 2022, then retreated 11.05% in 2025.
• A 5-year view of Common Equity shows it stood at $13.9 billion in 2022, then advanced by 26.36% to $17.6 billion in 2023, then decreased by 6.66% to $16.4 billion in 2024, then increased by 13.75% to $18.7 billion in 2025, then grew by 3.73% to $19.4 billion in 2026.
• The last three Common Equity figures came in at $19.4 billion (Q1 2026), $18.7 billion (Q4 2025), and $17.3 billion (Q3 2025), per Business Quant data.